Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma

Summary

The trial is performed to assess efficacy and safety of the Allergopharma house dust mite allergoid in bronchial asthma.

Timeline

Start

2005-05

Primary completion

2009-04

Completion

2012-08

Outcome

Met primary endpoint

paper significantly reduce the FP dose by more steps (P < .05), compared with the control group PMID 20624650 ↗

Publications

• Results Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol. 2010 Nov;126(5):942-9. doi: 10.1016/j.jaci.2010.06.002. Epub 2010 Jul 10.

Drugs

Indications